Article
Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.
Clinical lung cancer - 1 Mar 2021
Suda Kenichi, Sakai Kazuko, Obata Keiko, Ohara Shuta, Fujino Toshio, Koga Takamasa, Hamada Akira, Soh Junichi, Nishio Kazuto, Mitsudomi Tetsuya
Abstract excerpt
BACKGROUND: Several clinical and preclinical studies suggest that non-small cell lung cancers (NSCLCs) with EGFR compound mutations were associated with lower efficacies of first-generation EGFR inhibitors than tumors with single EGFR mutation. Some researchers hypothesize that EGFR mutation status is heterogeneous in such tumors and that second-generation EGFR inhibitors may eliminate cancer cells with uncommon...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.